This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.

Oncotype IQ Products
Oncotype IQ
Actionable genomic intelligence to inform cancer treatment decisions across the patient journey

Every cancer is unique and affects each diagnosed person differently, based on the individual biology of their disease.

To address this diversity and make cancer care smarter, our Oncotype IQ™ diagnostic tests and services portfolio delivers clinically relevant genomic intelligence that reveals the individual biology of a patient’s tumour.

Today, this additional genomic insight helps doctors optimise treatment decisions for early-stage breast, colon and prostate cancers. In the future we believe it will do the same at every stage of the cancer-care continuum.

Currently, the Oncotype IQ portfolio consists principally of Oncotype DX – our flagship line of gene expression tests that has been used to guide treatment decisions for more than half a million cancer patients worldwide and helped define a standard of care in precision medicine by making genomics a critical part of cancer diagnosis and treatment.

Our portfolio of tests and services is expanding. Our ongoing product development programs will include tissue and liquid-based gene mutation panels, monitoring tests to track tumour status and an easily accessible, web-based information platform to gather and help evaluate patient test results over time.

Oncotype DX: Defining Treatment Options and Personalising Decisions

The Oncotype DX diagnostic tests analyse the activity of selected sets of genes in a patient’s tumour tissue sample, in order to gain personalised biological information to optimise treatment decisions for breast, prostate and colon cancer patients. 

Our Product Pipeline

Genomic Health has plans to develop new diagnostic tests for tumour typing and tumour tracking that address critical treatment questions throughout each of the many stages of cancer.